A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
Completed · Phase 2
Conditions studied: Arthritis, Psoriatic, Psoriasis
In brief
This is a placebo controlled study evaluating the role of fludarabine (a nucleoside analog targeting both resting and proliferating lymphocytes) in the treatment of moderate to severe psoriotic arthritis. Patients should have failed at least one disease modifying antirheumatic drug.
Key facts
- Study ID
- NCT00001422
- Run by
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- People needed
- 20
- Starts
- 1995-06-01
- Expected to finish
- 2000-04-01
- Last updated by the study team
- 2008-03-04
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.